Literature DB >> 19567411

Editorial: Therapeutic potential of targeting BTLA.

Alison Crawford, E John Wherry.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19567411     DOI： 10.1189/JLB.0209076

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN： 0741-5400            Impact factor:   4.962


× No keyword cloud information.
  6 in total

Review 1.  Tumor-induced disruption of proximal TCR-mediated signal transduction in tumor-infiltrating CD8+ lymphocytes inactivates antitumor effector phase.

Authors:  Edwin J Vazquez-Cintron; Ngozi R Monu; Alan B Frey
Journal:  J Immunol       Date:  2010-12-15       Impact factor: 5.422

2.  Divide and conquer: Blocking graft versus host but not graft versus leukemia T cells with agonist BTLA co-inhibitory signals.

Authors:  Govindarajan Thangavelu; Colin C Anderson
Journal:  Chimerism       Date:  2011-01

Review 3.  Novel antibodies targeting immune regulatory checkpoints for cancer therapy.

Authors:  Chern Siang Lee; Mark Cragg; Martin Glennie; Peter Johnson
Journal:  Br J Clin Pharmacol       Date:  2013-08       Impact factor: 4.335

4.  Enhanced Innate Inflammation Induced by Anti-BTLA Antibody in Dual Insult Model of Hemorrhagic Shock/Sepsis.

Authors:  Tingting Cheng; Jianwen Bai; Chun-Shiang Chung; Yaping Chen; Bethany M Biron; Alfred Ayala
Journal:  Shock       Date:  2016-01       Impact factor: 3.454

Review 5.  Targeting Immune Cell Checkpoints during Sepsis.

Authors:  Naeem K Patil; Yin Guo; Liming Luan; Edward R Sherwood
Journal:  Int J Mol Sci       Date:  2017-11-14       Impact factor: 5.923

Review 6.  BTLA/HVEM Signaling: Milestones in Research and Role in Chronic Hepatitis B Virus Infection.

Authors:  Xueping Yu; Yijuan Zheng; Richeng Mao; Zhijun Su; Jiming Zhang
Journal:  Front Immunol       Date:  2019-03-29       Impact factor: 7.561
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.